Nancy Thornberry insider trades: Denali Therapeutics (DNLI) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Nancy reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | DNLI | ↓ Sell | 11,439 | $22.90 | $262K | Direct | Sep 4, 2026 (2d) |
| May 22, 2023 | SDGR | ↓ Sell | 14,850 | $35.00 | $520K | Direct | May 23, 2023 (1d) |
| Aug 11, 2022 | SDGR | ↓ Sell | 4,950 | $35.00 | $173K | Direct | Aug 12, 2022 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other DNLI insiders
Open-market trades in the last 12 months
About Nancy Thornberry's insider trades
Nancy Thornberry is a director at Denali Therapeutics (DNLI). Since Aug 11, 2022, Nancy has reported no open-market purchases and 3 sales worth $955K on SEC Form 4. In the last 12 months: 1 sale ($262K).
Their filings also include grants and awards (17 filings), option exercises (2 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DNLI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.